Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials.
Pulmonary disease is the leading cause of morbidity and mortality in patients with systemic sclerosis (SSc). Recent well-designed trials in SSc-associated interstitial lung disease (SSc-ILD) have provided important insights regarding outcome measures and trial design. Recent investigations into the pathogenesis of SSc-ILD have led to a renewed interest in assessing targeted therapies in SSc-ILD. With this in mind, we propose recommendations for the design of future SSc-ILD studies in this review.
Khanna
Dinesh
D
Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. dkhanna@mednet.ucla.edu
Brown
Kevin K
KK
Clements
Philip J
PJ
Elashoff
Robert
R
Furst
Daniel E
DE
Goldin
Jonathan
J
Seibold
James R
JR
Silver
Richard M
RM
Tashkin
Donald P
DP
Wells
Athol U
AU
D023381:Endpoint Determination; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012595:Scleroderma, Systemic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014797:Vital Capacity